Nemaura Medical Inc. (NMRD)

NASDAQ: NMRD · IEX Real-Time Price · USD
0.710
-0.016 (-2.16%)
At close: Mar 21, 2023, 4:00 PM
0.746
+0.036 (5.00%)
After-hours: Mar 21, 2023, 5:07 PM EDT
-2.16%
Market Cap 22.37M
Revenue (ttm) 397,322
Net Income (ttm) -13.08M
Shares Out 31.51M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,988
Open 0.700
Previous Close 0.726
Day's Range 0.700 - 0.773
52-Week Range 0.700 - 4.576
Beta -0.02
Analysts Buy
Price Target 8.84 (+1,145.07%)
Earnings Date Feb 24, 2023

About NMRD

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2009
Employees 32
Stock Exchange NASDAQ
Ticker Symbol NMRD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for NMRD stock is "Buy." The 12-month stock price forecast is $8.84, which is an increase of 1,145.07% from the latest price.

Price Target
$8.84
(1,145.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton

LOUGHBOROUGH, March 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.  (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...

19 hours ago - GlobeNewsWire

Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement

LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.  (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...

6 days ago - GlobeNewsWire

Nemaura Medical Announces Receipt of Notice from Nasdaq

LOUGHBOROUGH, March 09, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive w...

1 week ago - GlobeNewsWire

Nemaura Medical, Inc. (NMRD) Reports Q3 Loss, Lags Revenue Estimates

Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of 61.11% and 98.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc...

3 weeks ago - Zacks Investment Research

Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update

Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-i...

3 weeks ago - GlobeNewsWire

Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference

Loughborough, England, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable sensors and ...

1 month ago - GlobeNewsWire

Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

LOUGHBOROUGH, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive w...

1 month ago - GlobeNewsWire

Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive w...

1 month ago - GlobeNewsWire

Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable...

1 month ago - Business Wire

Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable...

2 months ago - Business Wire

Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference

Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de...

2 months ago - GlobeNewsWire

Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022

Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de...

3 months ago - GlobeNewsWire

Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom

LOUGHBOROUGH, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive we...

4 months ago - GlobeNewsWire

Nemaura Medical, Inc. (NMRD) Reports Q2 Loss, Misses Revenue Estimates

Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of 0% and 75.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Nemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors Conference

Loughborough, England, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de...

4 months ago - GlobeNewsWire

Nemaura Medical, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / November 4, 2022 / RedChip Companies will air a new interview with Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on ...

4 months ago - Accesswire

Nemaura Receives Provisional Purchase Order from Middle East Licensee TPMENA

LOUGHBOROUGH, ENGLAND, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising nonin...

5 months ago - GlobeNewsWire

Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura's Diabetes Management Program in the U.S.

CHICAGO and LOUGHBOROUGH, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non...

6 months ago - GlobeNewsWire

Nemaura Medical to Present at the 24th Annual H.C. Wainwright Global Investment Conference

Loughborough, England, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable gluc...

7 months ago - GlobeNewsWire

Nemaura Medical, Inc. (NMRD) Reports Q1 Loss, Lags Revenue Estimates

Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of -6.25% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Nemaura Medical Reports Fiscal First Quarter 2023 Results and Provides Business Update

Loughborough, England, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a dai...

7 months ago - GlobeNewsWire

Nemaura Medical Strengthens Balance Sheet with Further Non-Dilutive Funding

Loughborough, England, May 23, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and sup...

10 months ago - GlobeNewsWire

MySugarWatch Continues Large-Scale Awareness Campaign Around Nemaura Medical's sugarBEAT Non-Invasive Continuous Glucose Monitor Commencing Direct-to-Consumer Campaign in Daily Mail

Loughborough, England, May 17, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and sup...

11 months ago - GlobeNewsWire

Nemaura Medical to Present at the Planet MicroCap Showcase 2022

Loughborough, England, April 25, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and s...

11 months ago - GlobeNewsWire

Nemaura Medical to Present at the Maxim Group 2022 Virtual Growth Conference

Loughborough, England, March 24, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and s...

1 year ago - GlobeNewsWire